Home/Filings/4/0000897069-23-001054
4//SEC Filing

Cambrian BioPharma Inc 4

Accession 0000897069-23-001054

CIK 0001829802other

Filed

Aug 1, 8:00 PM ET

Accepted

Aug 2, 5:09 PM ET

Size

5.7 KB

Accession

0000897069-23-001054

Insider Transaction Report

Form 4
Period: 2023-07-31
Transactions
  • Disposition to Issuer

    Common Stock

    2023-07-31$1.26/sh1,587,302$2,000,0013,653,120 total
Footnotes (2)
  • [F1]Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and James Peyer. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.
  • [F2]These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

Documents

1 file

Issuer

Sensei Biotherapeutics, Inc.

CIK 0001829802

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001797409

Filing Metadata

Form type
4
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 5:09 PM ET
Size
5.7 KB